Heres the important context: weight loss on any intervention, including a GLP-1 medication, is almost never a smooth downward line
Folgt aus der antioxidativen Wirkung von GHK-Cu auf melanogene Prozesse
Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex
Sharma B, Dabur R
Nutritional monitoring becomes particularly important during aggressive weight loss phases, though this should be assessed on an individual basis
CJC 1295, ipamorelin, and retatrutide are synthetic peptides short chains of amino acids that have attracted growing interest in fitness, weight management, and certain online wellness communities
